The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells

Selective elimination of BRCA1-deficient cells by inhibitors of poly(ADP-ribose) polymerase (PARP) is a prime example of the concept of synthetic lethality in cancer therapy. This interaction is counteracted by the restoration of BRCA1-independent homologous recombination through loss of factors such as 53BP1, RIF1, and REV7/MAD2L2, which inhibit end resection of DNA double-strand breaks (DSBs). To identify additional factors involved in this process, we performed CRISPR/SpCas9-based loss-of-function screens and selected for factors that confer PARP inhibitor (PARPi) resistance in BRCA1-deficient cells. Loss of members of the CTC1-STN1-TEN1 (CST) complex were found to cause PARPi resistance in BRCA1-deficient cells in vitro and in vivo. We show that CTC1 depletion results in the restoration of end resection and that the CST complex may act downstream of 53BP1/RIF1. These data suggest that, in addition to its role in protecting telomeres, the CST complex also contributes to protecting DSBs from end resection. Using CRISPR/SpCas9-based loss-of-function screens, Barazas et al. show that loss of the CTC1-STN1-TEN1 (CST) complex promotes PARP inhibitor resistance in BRCA1-deficient cells. Mechanistically, the CST complex maintains double-strand break end stability in addition to its role in protecting telomeric ends

Understanding Chromosomal Translocation Formation in Human Cells

Les translocations chromosomiques qui consistent en l’échange de morceaux de chromosomes sont une des caractéristiques génétiques de nombreux cancers. Les séquences des jonctions des chromosomes transloqués chez les patients correspondent à une réparation par NHEJ. Nous avons étudié le rôle du complexe de ligation XRCC4/LigaseIV du C-NHEJ dans la formation de ces réarrangements chromosomiques dans les cellules humaines. Nous avons utilisé différentes nucléases artificielles (ZFN, TALEN, et CRISPR/Cas9) afin d'introduire deux CDB sur deux chromosomes et nous avons ainsi réussi à générer différentes translocations. Des lignées sauvages et mutantes pour ce complexe de ligation ont été utilisées et la fréquence formation de translocations a été quantifiée par PCR. Nous avons pu observer que celle-ci est souvent diminuée dans les différentes lignées mutantes. Les jonctions des translocations obtenues par séquençage sont modifiées dans des cellules déficientes pour ce complexe. En effet, elles présentent de longues délétions et un biais d’utilisation de microhomologies, indiquant l’utilisation d’un mécanisme alt-NHEJ. Une altération de cette voie dans les cellules humaines n’affecte d’ailleurs pas la formation de ces réarrangements chromosomiques. Ainsi, contrairement aux cellules de souris, les translocations dans les cellules humaines sont générées par le C-NHEJ.Chromosomal translocations involve the exchange of chromosome pieces and are often associated with oncogenesis. It has been shown that breakpoint junctions of translocated chromosomes found in patients are typical of a repair by NHEJ. Here we investigated the specific role of XRCC4/LigaseIV, the ligation complex of C-NHEJ, on chromosomal translocation formation in human cells. Using different nucleases (ZFN, TALEN, et CRISPR/Cas9) targeting two chromosomes, we studied the induction of translocation in wt and KO human cells, expressing or not the XRCC4/LigaseIV complex. We found that translocation frequency was mostly reduced in XRCC4/LigaseIV deficient cells when we quantified the induction of translocation by PCR. In addition, we analyzed the breakpoint junctions by sequencing. Strikingly, we found that junctions of translocations show large deletions, and a bias towards the use of longer microhomologies only in XRCC4/LigaseIV KO cells, signature of the alt-NHEJ activity. In contrast, translocation formation was not affected in alt-NHEJ deficient cells. Thus conflicting with results obtained in rodent cells where alt-NHEJ promotes translocation formation, translocations in human cells are generated by the C-NHEJ

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

Selective elimination of BRCA1-deficient cells by inhibitors of poly(ADP-ribose) polymerase (PARP) is a prime example of the concept of synthetic lethality in cancer therapy. This interaction is counteracted by the restoration of BRCA1-independent homologous recombination through loss of factors such as 53BP1, RIF1, and REV7/MAD2L2, which inhibit end resection of DNA double-strand breaks (DSBs). To identify additional factors involved in this process, we performed CRISPR/SpCas9-based loss-of-function screens and selected for factors that confer PARP inhibitor (PARPi) resistance in BRCA1-deficient cells. Loss of members of the CTC1-STN1-TEN1 (CST) complex were found to cause PARPi resistance in BRCA1-deficient cells in vitro and in vivo. We show that CTC1 depletion results in the restoration of end resection and that the CST complex may act downstream of 53BP1/RIF1. These data suggest that, in addition to its role in protecting telomeres, the CST complex also contributes to protecting DSBs from end resection

53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ.

53BP1 governs a specialized, context-specific branch of the classical non-homologous end joining DNA double-strand break repair pathway. Mice lacking 53bp1 (also known as Trp53bp1) are immunodeficient owing to a complete loss of immunoglobulin class-switch recombination, and reduced fidelity of long-range V(D)J recombination. The 53BP1-dependent pathway is also responsible for pathological joining events at dysfunctional telomeres, and its unrestricted activity in Brca1-deficient cellular and tumour models causes genomic instability and oncogenesis. Cells that lack core non-homologous end joining proteins are profoundly radiosensitive, unlike 53BP1-deficient cells, which suggests that 53BP1 and its co-factors act on specific DNA substrates. Here we show that 53BP1 cooperates with its downstream effector protein REV7 to promote non-homologous end joining during class-switch recombination, but REV7 is not required for 53BP1-dependent V(D)J recombination. We identify shieldin-a four-subunit putative single-stranded DNA-binding complex comprising REV7, c20orf196 (SHLD1), FAM35A (SHLD2) and FLJ26957 (SHLD3)-as the factor that explains this specificity. Shieldin is essential for REV7-dependent DNA end-protection and non-homologous end joining during class-switch recombination, and supports toxic non-homologous end joining in Brca1-deficient cells, yet is dispensable for REV7-dependent interstrand cross-link repair. The 53BP1 pathway therefore comprises distinct double-strand break repair activities within chromatin and single-stranded DNA compartments, which explains both the immunological differences between 53bp1- and Rev7- deficient mice and the context specificity of the pathway